Literature DB >> 1692764

Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidized dextrans of low molecular weight.

R Fagnani1, M S Hagan, R Bartholomew.   

Abstract

This communication describes the covalent modification of monoclonal and polyclonal antibodies with oxidized dextrans of low molecular weight to generate conjugates having low immunogenicity in vivo. Conjugation conditions were optimized to generate monomeric, dextran-modified antibodies, free of both high-molecular-weight polymeric aggregates and unmodified antibodies. Conjugates could be prepared with varying levels of dextran substitution. These conjugates retained optimal immunoreactivity as well as in vivo pharmacokinetics and tumor-localization properties. In addition, multiple i.v. administrations of dextran-modified antibodies in animals did not elicit a measurable immune response to either the antibody or the dextran portion of these conjugates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692764

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin.

Authors:  Kyohei Yumura; Mihoko Ui; Hirofumi Doi; Takao Hamakubo; Tatsuhiko Kodama; Kouhei Tsumoto; Akira Sugiyama
Journal:  Protein Sci       Date:  2013-01-04       Impact factor: 6.725

3.  Reduced antibody response to streptavidin through site-directed mutagenesis.

Authors:  D L Meyer; J Schultz; Y Lin; A Henry; J Sanderson; J M Jackson; S Goshorn; A R Rees; S S Graves
Journal:  Protein Sci       Date:  2001-03       Impact factor: 6.725

Review 4.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

5.  Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol.

Authors:  K Takashina; K Kitamura; T Yamaguchi; A Noguchi; A Noguchi; H Tsurumi; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1991-10

6.  Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold.

Authors:  Hendrik Schneider; Lukas Deweid; Thomas Pirzer; Desislava Yanakieva; Simon Englert; Bastian Becker; Olga Avrutina; Harald Kolmar
Journal:  ChemistryOpen       Date:  2019-03-28       Impact factor: 2.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.